VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 467-475

  Marinova, Milka ^a   Lütjohann, Dieter ^a   Breuer, Olof ^a   Kölsch, Heike ^a   Westhofen, Philipp ^a   Watzka, Matthias ^a   Mengel, Martin ^a   Stoffel Wagner, Birgit ^a   Hartmann, Gunther ^a   Coch, Christoph ^a   Oldenburg, Johannes ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Bioavailability; Chromatography; Clearance; Clinical study; Coagulation; Pharmacokinetics; Phylloquinone

Indexed keywords

ADENINE; CYTOSINE; GUANINE; OXIDOREDUCTASE; PHYTOMENADIONE; THYMINE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1;

ABCC6 GENE; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; COLUMN CHROMATOGRAPHY; CYP4F2 GENE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; FLUOROMETRY; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLE; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VKORC1 GENE;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; FEMALE; FLUOROMETRY; GERMANY; HALF-LIFE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INJECTIONS, INTRAVENOUS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MICELLES; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; VITAMIN K 1; VITAMINS; YOUNG ADULT;

EID: 84877121987     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1362-y     Document Type: Article

References (36)

1. Shearer MJ (1995) Vitamin K. Lancet 345:229-234
2. Shearer MJ (2000) Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 3:433-438
3. Oldenburg J, Marinova M, Muller-Reible C, Watzka M (2008) The vitamin K cycle. Vitam Horm 78:35-62
4. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541
5. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427:541-544
6. Whitlon DS, Sadowski JA, Suttie JW (1978) Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 17:1371-1377
7. Oldenburg J, Bevans CG, Muller CR, Watzka M (2006) Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 8:347-353
8. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43:740-744
9. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94:773-779
10. Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J (2006) The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 133:183-187
11. Oldenburg J, Bevans CG, Fregin A, Geisen C, Muller-Reible C, Watzka M (2007) Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 98:570-578
12. Oldenburg J, Watzka M, Rost S, Muller CR (2007) VKORC1: molecular target of coumarins. J Thromb Haemost 5 [Suppl 1]:1-6
13. Suttie JW (1992) Vitamin K and human nutrition. J Am Diet Assoc 92:585-590
14. Shearer MJ, McBurney A, Barkhan P (1974) Studies on the absorption and metabolism of phylloquinone (vitamin K1) in man. Vitam Horm 32:513-542
15. Savage D, Lindenbaum J (1983) Clinical and experimental human vitamin K deficiency. In: Lindenbaum J (ed) Nutrition in hematology. Churchill Livingstone, New York, pp 271-320
16. Kohlmeier M, Saupe J, Drossel HJ, Shearer MJ (1995) Variation of phylloquinone (vitamin K1) concentrations in hemodialysis patients. Thromb Haemost 74:1252-1254
17. Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ (1998) Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am J Clin Nutr 67:1226-1231
18. Schurgers LJ, Vermeer C (2002) Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim Biophys Acta 1570:27-32
19. Shea MK, Benjamin EJ, Dupuis J, Massaro JM, Jacques PF, D'Agostino RB Sr, Ordovas JM, O'Donnell CJ, Dawson-Hughes B, Vasan RS, Booth SL (2009) Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr 63:458-464
20. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE (2009) CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75:1337-1346
21. Schulz V, Hendig D, Henjakovic M, Szliska C, Kleesiek K, Gotting C (2006) Mutational analysis of the ABCC6 gene and the proximal ABCC6 gene promoter in German patients with pseudoxanthoma elasticum (PXE). Hum Mutat 27:831
22. Vanakker OM, Martin L, Schurgers LJ, Quaglino D, Costrop L, Vermeer C, Pasquali-Ronchetti I, Coucke PJ, De Paepe A (2010) Low serum vitamin K in PXE results in defective carboxylation of mineralization inhibitors similar to the GGCX mutations in the PXE-like syndrome. Lab Invest 90:895-905
23. EMEA (2006) Guideline for good clinical practice ICH harmonised tripartite guideline
24. Roche (2007) Konakion MM 2 mg. Specialist information
25. Roche (2007) Konakion MM 10 mg. Specialist information
26. Watzka M, Nebel A, El Mokhtari NE, Ivandic B, Muller J, Schreiber S, Oldenburg J (2007) Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans. Thromb Haemost 97:998-1002
27. Borst P, van de Wetering K, Schlingemann R (2008) Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery? Cell Cycle 7:1575-1579
28. Marinova M, Lütjohann D, Westhofen P, Watzka M, Breuer O, Oldenburg J (2011) A validated HPLC method for the determination of vitamin K in human serum - first application in a pharmacological study. Open Clin Chem J DOI: 10.2174/1874241601104010017
29. Card DJ, Shearer MJ, Schurgers LJ, Harrington DJ (2009) The external quality assurance of phylloquinone (vitamin K(1)) analysis in human serum. Biomed Chromatogr 23:1276-1282
30. Koivu-Tikkanen TJ, Ollilainen V, Piironen VI (2000) Determination of phylloquinone and menaquinones in animal products with fluorescence detection after postcolumn reduction with metallic zinc. J Agric Food Chem 48:6325-6331
31. Soedirman JR, De Bruijn EA, Maes RA, Hanck A, Gruter J (1996) Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation. Br J Clin Pharmacol 41:517-523
32. Jones KS, Bluck LJ, Wang LY, Coward WA (2008) A stable isotope method for the simultaneous measurement of vitamin K(1) (phylloquinone) kinetics and absorption. Eur J Clin Nutr 62:1273-1281
33. Raith W, Fauler G, Pichler G, Muntean W (2000) Plasma concentrations after intravenous administration of phylloquinone (vitamin K(1)) in preterm and sick neonates. Thromb Res 99:467-472
34. Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R (2005) Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol 42:365-370
35. Pereira SP, Shearer MJ, Williams R, Mieli-Vergani G (2003) Intestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants with conjugated hyperbilirubinaemia: implications for oral prophylaxis of vitamin K deficiency bleeding. Arch Dis Child Fetal Neonatal Ed 88:F113-F118
36. Shearer MJ, Newman P (2008) Metabolism and cell biology of vitamin K. Thromb Haemost 100:530-547